Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Vabysmo 120 mg/mL solution for injection in pre-filled syringe
The George Institute
SUBRETINAL HYPERREFLECTIVE MATERIAL
1 trial -
Valbenazine Oral Capsule
NEUROCRINE BIOSCIENCES INC
Tardive Dyskinesia
1 trial -
Valproic acid
Hospital Authority, Hong Kong
Drug Resistant Epilepsy
1 trial -
Vancomycin
The First People's Hospital of Lianyungang
Blood Stream Infections
1 trial -
Vardenafil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Erectile Dysfunction
1 trial -
Vaxigrip Tetra, suspensie voor injectie in een voorgevulde spuit Quadrivalent griepvaccin (gesplitst virion, geΓ―nactiveerd), Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)
Disc Medicine
healthy individuals
1 trial -
Venetoclax
AbbVie
Acute Myeloid Leukemia (AML)
1 trial -
Vifor
The First People's Hospital of Lianyungang
Malnutrition
1 trial -
Vitamine E-400 complex, Microgynon 30, 0,15 mg/0,03 mg omhulde tabletten
Disc Medicine
Migraine
1 trial -
Voltaren SPORT, 11,6 mg/g, ΕΌel, Voltaren MAX, 23,2 mg/g, ΕΌel
HALEON AUSTRALIA PTY LTD
Mild/non-serious osteoarthritis (OA) of the knee.
1 trial -
Vonoprazan
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
2 trials -
Vonoprazan
The First People's Hospital of Lianyungang
Ulcers, Gastric
1 trial -
Vonoprazan and Amoxicillin for the first 7 days
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial -
Vyndaqel 61 mg soft capsules
Monte Rosa Therapeutics
Transthyretin cardiac amyloidosis
1 trial -
WARFARIN, LYSINE ASPIRIN, CLOPIDOGREL, ACETYLSALICYLIC ACID, ATORVASTATIN, DILTIAZEM, BISOPROLOL, ACETYLCHOLINE CHLORIDE, GLYCERYL TRINITRATE, RAMIPRIL
Fondazione Telethon ETS
Myocardial infarction with non-obstructive coronary arteries (MINOCA)
1 trial -
Wangbi granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis
1 trial -
Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
NovoThirteen
Obesity
1 trial -
Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen
Lacuna Pharma Pty Ltd
Adipositas
1 trial -
Wegovy 2.4 mg solution for injection in pre-filled pen
The George Institute
obstructive sleep apnea
1 trial -
Wen Xin granule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
XALKORI 200 mg hard capsules, XALKORI 250 mg hard capsules, Crizotinib 200 mg capsules, Crizotinib 250 mg capsules
Pfizer Australia Pty Ltd
This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
1 trial -
XELJANZ 11 mg prolonged-release tablets
Disc Medicine
Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria
1 trial -
Xingnaojing injection
The First People's Hospital of Lianyungang
Ischemic Stroke, Acute
1 trial -
Xinnaoning Capsule
BRIGHT MINDS BIOSCIENCES INC.
Chronic Stable Angina Pectoris
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources